Key Details
Annual ROE
-31.49%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Mar 22, 2024Recent annual earnings:
Mar 22, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
05 Jan '24 B of A Securities
Underperform12 May '23 Wedbush
Outperform03 Feb '23 Morgan Stanley
Underweight30 Jan '23 B of A Securities
Neutral20 Jan '23 JP Morgan
Neutral09 Sept '22 Morgan Stanley
Equal-Weight17 Mar '22 Wedbush
Outperform07 Feb '22 Northland Capital Markets
Outperform13 July '21 Wedbush
Outperform13 July '21 Morgan Stanley
OverweightScreeners with CYT included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Cyteir Therapeutics doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
Cyteir: Although The Company Is Winding Down, The Lead Asset Had Promise
CYT
Seeking Alpha18 September 2023
Cyteir is a developer of cancer therapeutics that has decided to suspend operations and sell all assets. Their lead candidate, CYT-0851, is an MCT1 inhibitor being investigated in combination with chemotherapy drugs. The drug has shown monotherapy activity in a phase 1 trial, but further development has been suspended.
FAQ
- What is the primary business of Cyteir Therapeutics?
- What is the ticker symbol for Cyteir Therapeutics?
- Does Cyteir Therapeutics pay dividends?
- What sector is Cyteir Therapeutics in?
- What industry is Cyteir Therapeutics in?
- What country is Cyteir Therapeutics based in?
- When did Cyteir Therapeutics go public?
- Is Cyteir Therapeutics in the S&P 500?
- Is Cyteir Therapeutics in the NASDAQ 100?
- Is Cyteir Therapeutics in the Dow Jones?
- When was Cyteir Therapeutics's last earnings report?
- When does Cyteir Therapeutics report earnings?
- Should I buy Cyteir Therapeutics stock now?
What is the primary business of Cyteir Therapeutics?
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.
What is the ticker symbol for Cyteir Therapeutics?
The ticker symbol for Cyteir Therapeutics is NASDAQ:CYT
Does Cyteir Therapeutics pay dividends?
No, Cyteir Therapeutics does not pay dividends
What sector is Cyteir Therapeutics in?
Cyteir Therapeutics is in the Healthcare sector
What industry is Cyteir Therapeutics in?
Cyteir Therapeutics is in the Biotechnology industry
What country is Cyteir Therapeutics based in?
Cyteir Therapeutics is headquartered in United States
When did Cyteir Therapeutics go public?
Cyteir Therapeutics's initial public offering (IPO) was on 18 June 2021
Is Cyteir Therapeutics in the S&P 500?
No, Cyteir Therapeutics is not included in the S&P 500 index
Is Cyteir Therapeutics in the NASDAQ 100?
No, Cyteir Therapeutics is not included in the NASDAQ 100 index
Is Cyteir Therapeutics in the Dow Jones?
No, Cyteir Therapeutics is not included in the Dow Jones index
When was Cyteir Therapeutics's last earnings report?
Cyteir Therapeutics's most recent earnings report was on 22 March 2024
When does Cyteir Therapeutics report earnings?
The date for Cyteir Therapeutics's next earnings report has not been announced yet
Should I buy Cyteir Therapeutics stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions